Company profile
Shuttle Pharmaceuticals Holdings, Inc.
NASDAQ:SHPHBiotechnology: Pharmaceutical Preparations
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06359379 | phase2 | terminated | 2024-09-02 | 2025-12-01 | Shuttle Pharmaceuticals, Inc. | Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter |
FDA applications (0)
No records yet.